Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan-Reference-Cited by-同舟云学术

Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan

Published:2022-08 Issue:8 Volume:121 Page:1567-1578
ISSN:0929-6646
Container-title:Journal of the Formosan Medical Association
language:en
Short-container-title:Journal of the Formosan Medical Association

Author:

Lo Ching-Chu^ORCID,Huang Chung-Feng,Cheng Pin-Nan,Tseng Kuo-Chih,Chen Chi-Yi,Kuo Hsing-Tao,Huang Yi-Hsiang^ORCID,Tai Chi-Ming,Peng Cheng-Yuan,Bair Ming-Jong,Chen Chien-Hung,Yeh Ming-Lun^ORCID,Lin Chih-Lang,Lin Chun-Yen,Lee Pei-Lun,Chong Lee-Won,Hung Chao-Hung,Chang Te Sheng,Huang Jee-Fu,Yang Chi-Chieh,Hu Jui-Ting,Lin Chih-Wen,Chen Chun-Ting,Wang Chia-Chi,Su Wei-Wen,Hsieh Tsai-Yuan,Lin Chih-Lin,Tsai Wei-Lun,Lee Tzong-Hsi,Chen Guei-Ying,Wang Szu-Jen,Chang Chun-Chao,Mo Lein-Ray,Yang Sheng-Shun,Wu Wen-Chih,Huang Chia-Sheng,Hsiung Chou-Kwok,Kao Chien-Neng,Tsai Pei-Chien,Liu Chen-Hua^ORCID,Lee Mei-Hsuan,Liu Chun-Jen,Dai Chia-Yen,Chuang Wan-Long^ORCID,Lin Han-Chieh,Kao Jia-Horng^ORCID,Yu Ming-Lung^ORCID

Publisher

Elsevier BV

Subject

General Medicine

Reference43 articles.

1. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study;Blach;Lancet Gastroenterol Hepatol,2017

2. Global progress report on HIV, viral hepatitis and sexually transmitted infections;WHO,2021

3. EASL recommendations on treatment of hepatitis C: final update of the series;Pawlotsky;J Hepatol,2020

4. HCV guidance: recommendations for testing, managing, and treating hepatitis C,2021

5. Outcomes of hepatitis C virus treatment with ledipasvir/sofosbuvir in Mongolian population: successes and challenges facing scale-up of care;Kang;Clin Mol Hepatol,2021

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Contemporary Insights into Hepatitis C Virus: A Comprehensive Review;Microorganisms;2024-05-21

2. Real-World Efficacy and Safety of Universal 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve Patients from a Nationwide HCV Registry in Taiwan;Infectious Diseases and Therapy;2024-04-28

3. Is it time for China to prioritize pan-genotypic regimens for treating patients with hepatitis C?;Cost Effectiveness and Resource Allocation;2024-02-06

4. Ledipasvir/Sofosbuvir in Hepatitis C Virus–Infected Children With Hematological Malignancies: A Pharmacokinetic Study;Clinical Therapeutics;2024-01